Clorox Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Clorox ha aumentado sus beneficios a una tasa media anual de 15.2%, mientras que los beneficios de la industria de Household Products han experimentado un crecimiento de 2.5% anual. Los ingresos han ido disminuyendo a una tasa media de 1.1% al año. La rentabilidad financiera de Clorox es de 238.5%, y sus márgenes netos son de 8.7%.
Información clave
15.21%
Tasa de crecimiento de los beneficios
15.58%
Tasa de crecimiento del BPA
| Crecimiento de la industria Household Products | 1.51% |
| Tasa de crecimiento de los ingresos | -1.07% |
| Rentabilidad financiera | 238.49% |
| Margen neto | 8.74% |
| Última actualización de beneficios | 30 Jun 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Seeking Alpha • Aug 21
Clorox: A Better Business, But Too Much Growth Is Priced In
Summary I reiterate a Hold rating on The Clorox Company, as the current valuation requires unsustainably high free cash flow growth. Recent positives include the GOJO acquisition and ERP rollout, but organic revenue growth remains limited after adjusting for these factors. CLX's balance sheet is heavily leveraged post-acquisition, constraining reinvestment and raising dividend sustainability concerns. Despite optimism around wellness trends, I see an insufficient margin of safety at current prices and recommend monitoring for a significant price drop. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 21
CLX: GOJO Integration And ERP Gains Will Support Long Term Earnings
The updated analyst price target for Clorox has shifted lower by about $8 per share, with analysts pointing to wider uncertainty around FY27 earnings, softer recent share trends and the potential for increased reinvestment under new leadership as key factors. Analyst Commentary Recent Street research on Clorox shows a mix of caution and optimism, with several bullish analysts lifting price targets even as others trim expectations on longer term earnings guidance.
Actualización de narrativa • Aug 06
CLX: GOJO Deal And Leadership Transition Will Shape Healthcare Portfolio Outlook
Clorox's updated analyst price target has shifted slightly lower to about $101.71, reflecting analysts' mixed revisions around FY27 earnings visibility, new leadership, and a wider range of potential outcomes highlighted in recent research. Analyst Commentary Recent research on Clorox shows a tight cluster of price targets around the high US$90s to low US$100s.Actualización de narrativa • Jul 23
CLX: GOJO Integration And Execution Improvements Will Support Long Term Earnings
For Clorox, the analyst price target has been trimmed by about $3 to reflect slightly lower modeled revenue growth and profit margins, even as recent Street research shows a mix of modest target hikes and cuts related to upcoming earnings and category trends. Analyst Commentary Recent Street research on Clorox shows a mix of trims and increases to price targets, with several bullish analysts highlighting potential for steadier execution and a more balanced risk and reward profile around upcoming earnings.
Actualización de narrativa • Jul 08
CLX: Mounting Execution Risks Around GOJO Integration Will Pressure Future Earnings Power
Clorox's analyst price target has been reduced by $6 to $77, as analysts factor in slightly more cautious revenue growth assumptions, a modestly higher profit margin outlook, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a clear tilt toward caution, with multiple bearish analysts trimming their price targets and one downgrade from JPMorgan adding to the negative tone.Artículo de análisis • Jun 16
Clorox (CLX) Stock Could Be 44% Below Fair Value Despite Recent Bounce
Clorox (CLX) stock has been drawing attention after recent performance figures showed mixed returns across different timeframes, prompting investors to reassess how the company’s current valuation lines up with its fundamentals and longer term track record. See our latest analysis for Clorox. At a share price of US$95.98, Clorox has seen its 30 day share price return rise 6.11%, while the 90 day share price return fell 13.84% and the 1 year total shareholder return declined 19.06%. This...Actualización de narrativa • Jun 13
CLX: GOJO Integration And Healthcare Expansion Will Shape Future Portfolio Multiple
Narrative Update The analyst price target for Clorox is updated lower from $115.47 to $105.29, reflecting a series of Street revisions as analysts factor in a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a broad reset in expectations, with multiple firms trimming price targets and at least one downgrade from JPMorgan.Actualización de narrativa • May 30
CLX: Execution Risks And Leadership Transition Will Constrain Future Earnings Power
Clorox's analyst fair value estimate has been revised down from $94.00 to $83.00 as analysts factor in updated assumptions around discount rates, margins, and future P/E, in light of a broad wave of recent price target cuts across the Street. Analyst Commentary Recent Street research has tilted clearly cautious on Clorox, with a series of price target cuts and at least one downgrade from JPMorgan.Actualización de narrativa • May 14
CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings
Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.Actualización de narrativa • Apr 29
CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple
Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.Actualización de narrativa • Apr 15
CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power
Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.Actualización de narrativa • Mar 31
CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power
Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.Actualización de narrativa • Mar 17
CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook
Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.Actualización de narrativa • Mar 03
CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power
Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.Actualización de narrativa • Feb 17
CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E
The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.Actualización de narrativa • Feb 03
CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple
Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.Actualización de narrativa • Jan 20
CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating
Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.Actualización de narrativa • Jan 05
CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating
Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.Actualización de narrativa • Dec 20
CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook
Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.Actualización de narrativa • Dec 05
CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery
Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.Actualización de narrativa • Nov 21
CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026
Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.Artículo de análisis • Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet
Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...Artículo de análisis • Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...Actualización de narrativa • Nov 06
CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026
Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.Actualización de narrativa • Oct 23
Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.Actualización de narrativa • Oct 09
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.Actualización de narrativa • Aug 27
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.Seeking Alpha • Mar 29
Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking AlphaDesglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Clorox. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 26 | 6,720 | 587 | 1,819 | 116 |
| 31 Mar 26 | 6,760 | 756 | 1,772 | 116 |
| 31 Dec 25 | 6,758 | 755 | 1,842 | 116 |
| 30 Sep 25 | 6,771 | 791 | 1,857 | 118 |
| 30 Jun 25 | 7,104 | 810 | 1,896 | 121 |
| 31 Mar 25 | 7,019 | 694 | 1,980 | 122 |
| 31 Dec 24 | 7,165 | 457 | 2,008 | 127 |
| 30 Sep 24 | 7,469 | 357 | 2,035 | 128 |
| 30 Jun 24 | 7,093 | 280 | 1,985 | 126 |
| 31 Mar 24 | 7,209 | 240 | 1,975 | 132 |
| 31 Dec 23 | 7,310 | 80 | 2,014 | 135 |
| 30 Sep 23 | 7,035 | 86 | 1,929 | 136 |
| 30 Jun 23 | 7,389 | 149 | 1,921 | 139 |
| 31 Mar 23 | 7,171 | 74 | 1,837 | 134 |
| 31 Dec 22 | 7,065 | 435 | 1,682 | 130 |
| 30 Sep 22 | 7,041 | 405 | 1,684 | 131 |
| 30 Jun 22 | 7,107 | 462 | 1,679 | 132 |
| 31 Mar 22 | 7,108 | 458 | 1,711 | 143 |
| 31 Dec 21 | 7,080 | 247 | 1,762 | 144 |
| 30 Sep 21 | 7,231 | 437 | 1,809 | 150 |
| 30 Jun 21 | 7,341 | 710 | 1,809 | 149 |
| 31 Mar 21 | 7,522 | 923 | 1,813 | 146 |
| 31 Dec 20 | 7,524 | 1,225 | 1,829 | 153 |
| 30 Sep 20 | 7,131 | 1,151 | 1,723 | 147 |
| 30 Jun 20 | 6,721 | 939 | 1,654 | 145 |
| 31 Mar 20 | 6,365 | 870 | 1,557 | 141 |
| 31 Dec 19 | 6,133 | 816 | 1,470 | 136 |
| 30 Sep 19 | 6,157 | 813 | 1,478 | 134 |
| 30 Jun 19 | 6,214 | 820 | 1,482 | 136 |
| 31 Mar 19 | 6,278 | 796 | 1,458 | 135 |
| 31 Dec 18 | 6,244 | 790 | 1,447 | 133 |
| 30 Sep 18 | 6,187 | 841 | 1,420 | 132 |
| 30 Jun 18 | 6,124 | 823 | 1,407 | 132 |
| 31 Mar 18 | 6,080 | 808 | 1,427 | 132 |
| 31 Dec 17 | 6,040 | 799 | 1,431 | 135 |
| 30 Sep 17 | 6,030 | 716 | 1,423 | 136 |
| 30 Jun 17 | 5,973 | 703 | 1,409 | 135 |
| 31 Mar 17 | 5,926 | 666 | 1,432 | 140 |
| 31 Dec 16 | 5,875 | 653 | 1,420 | 140 |
| 30 Sep 16 | 5,814 | 654 | 1,412 | 142 |
| 30 Jun 16 | 5,761 | 648 | 1,393 | 141 |
| 31 Mar 16 | 5,718 | 672 | 1,348 | 138 |
| 31 Dec 15 | 5,693 | 657 | 1,328 | 137 |
| 30 Sep 15 | 5,693 | 634 | 1,329 | 136 |
Ingresos de calidad: CLX tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(8.7%) de CLX son inferiores a los del año pasado (11.4%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de CLX han crecido un 15.2% al año en los últimos 5 años.
Acelerando crecimiento: CLX ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: CLX tuvo un crecimiento negativo de los beneficios (-27.5%) durante el año pasado, lo que dificulta la comparación con la media de la industria Household Products (11.6%).
Rentabilidad financiera
Alta ROE: Aunque la rentabilidad financiera (238.49%) de CLX es excepcional, esta métrica está sesgada debido a su alto nivel de deuda.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/18 19:35 |
| Precio de las acciones al final del día | 2026/09/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
The Clorox Company está cubierta por 29 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| John Staszak | Argus Research Company |
| Lauren Lieberman | Barclays |
| Constance Maneaty | BMO Capital Markets Equity Research |